Tomorrow.Bio, a German-based company in the cryonics sector, aims to redefine how humans perceive life and mortality. Recently, the company concluded the first stage of a €5M equity funding round, with ambitions to broaden its footprint into the United States. Cryonics, the technique of preserving individuals at extremely low temperatures after legal death, holds the promise of a future return to life as medical technologies advance. Tomorrow.Bio has positioned itself at the forefront of this experimental field, drawing significant interest and investment.
In the past, attempts at cryonics faced skepticism and technological challenges. Companies from as far back as the 1960s proposed cryonic preservation, yet without substantial commercial success. Recent advancements, however, have spurred renewed interest, with Tomorrow.Bio tackling previous hurdles through refined cryopreservation methods and enhanced technological capabilities. This latest funding round signifies a substantial step forward for a company aiming to establish a footprint in the global cryonics market.
What Drives This Investment?
Tomorrow.Bio has outlined a strategic plan for the use of the newly acquired funds, targeting expansion and research. With capital backing from investors including Blast.Club and TruVenturo, the company intends to strengthen their research and development, improving preservation quality and global reach. This financial boost will also help pave the way for new facilities, initially focusing on New York, California, and Florida.
We’re extremely happy to have found visionary investors to continue our long-term mission.
How Will Tomorrow.Bio Tackle Cryonics in the US?
The firm plans to create local support teams to provide immediate cryopreservation services upon confirmation of legal death. These teams aim to efficiently transport individuals to Tomorrow.Bio’s Swiss facility, utilizing cryo-ambulances to begin the cooling process as soon as possible. The company’s strategic alignment with the European Biostasis Foundation further bolsters its logistical and operational capacities in the preservation niche.
Beyond human preservation, Tomorrow.Bio extends its services to pets, emphasizing its versatile use of cryonics technology. A significant tally of contracts shows over 800 individuals registered for future procedures, reflecting growing public interest in life extension possibilities. This bold expansion into the US market underlines the belief in the potential of cryonics.
Tomorrow.Bio’s advancements reveal a calculated effort to address the technological difficulties traditionally associated with cryonic preservation. Deploying vacuum-insulated steel containers devoid of electricity, the company ensures ultralow temperatures for long-term storage, an essential factor for maintaining frozen bodies until revival technology is viable.
By stepping into the US territory with established partners, Tomorrow.Bio makes strides towards realizing its ambitious goal: providing an advanced option for preserving life, ready for future re-animation. As the discourse on life preservation evolves, such endeavors will contribute significantly to the understanding and potential acceptance of cryonics.
Cryonics remains a debated topic, yet Tomorrow.Bio’s ongoing efforts to improve technology and expand its reach provide fresh momentum in the field. By focusing on both technological advancement and geographical expansion, the company aims to offer innovative solutions for enhancing life’s possibilities. This marks a turning point in how society could potentially perceive life and death in the years to come.